FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129816339> ?p ?o ?g. }

• W2129816339 abstract "Successful treatments of patients with somatostatin receptor (SSTR)-overexpressing neuroendocrine tumours (NET) comprise somatostatin-analogue lutetium-177-labelled octreotate (177Lu-TATE) treatment, also referred to as peptide receptor radionuclide therapy (PRRT), and temozolomide (TMZ) treatment. Their combination might result in additive effects. Using MRI and SPECT/CT, we studied tumour characteristics and therapeutic responses after different (combined) administration schemes in a murine tumour model in order to identify the optimal treatment schedule for PRRT plus TMZ. We performed molecular imaging studies in mice bearing SSTR-expressing H69 (humane small cell lung cancer) tumours after single intravenous (i.v.) administration of 30 MBq 177Lu-TATE or TMZ (oral 50 mg/kg daily for 14 days). Tumour perfusion was evaluated weekly by dynamic contrast-enhanced MRI (DCE-MRI), whereas tumour uptake of 111In-octreotide was quantified using SPECT/CT until day 39 after treatment. Based on these results, seven different 177Lu-octreotate and TMZ combination schemes were evaluated for therapy response, varying the order and time interval of the two therapies and compared with single treatments. PRRT and TMZ both resulted in tumour size reduction, accompanied by significant changes in MRI characteristics such as an enhanced tumour perfusion. Moreover, TMZ treatment also resulted in increased uptake of the SST analogue 111In-octreotide until day 13. In the subsequent therapy study, 90 % of animals receiving 177Lu-TATE at day 14 after TMZ treatment showed complete response, being the best anti-tumour results among groups. Molecular imaging studies indicated that PRRT after TMZ treatment could induce optimal therapeutic effects because of enhanced tumour uptake of radioactivity after TMZ, which was confirmed by therapy responses. Therefore, clinical translation of TMZ treatment prior to PRRT might increase tumour responses in NET patients as well." @default.
• W2129816339 created "2016-06-24" @default.
• W2129816339 creator A5002069722 @default.
• W2129816339 creator A5011666650 @default.
• W2129816339 creator A5023339336 @default.
• W2129816339 creator A5026596873 @default.
• W2129816339 creator A5030459772 @default.
• W2129816339 creator A5034821195 @default.
• W2129816339 creator A5040369608 @default.
• W2129816339 creator A5056704467 @default.
• W2129816339 creator A5079645152 @default.
• W2129816339 date "2015-11-09" @default.
• W2129816339 modified "2023-10-09" @default.
• W2129816339 title "Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies" @default.
• W2129816339 cites W1792626212 @default.
• W2129816339 cites W1935825021 @default.
• W2129816339 cites W1970020829 @default.
• W2129816339 cites W1993365120 @default.
• W2129816339 cites W2001446629 @default.
• W2129816339 cites W2008997722 @default.
• W2129816339 cites W2012856564 @default.
• W2129816339 cites W2017007251 @default.
• W2129816339 cites W2019911597 @default.
• W2129816339 cites W2024930137 @default.
• W2129816339 cites W2026241236 @default.
• W2129816339 cites W2027676394 @default.
• W2129816339 cites W2028499378 @default.
• W2129816339 cites W2029982124 @default.
• W2129816339 cites W2030568152 @default.
• W2129816339 cites W2032598681 @default.
• W2129816339 cites W2035218324 @default.
• W2129816339 cites W2042098439 @default.
• W2129816339 cites W2067884125 @default.
• W2129816339 cites W2072470605 @default.
• W2129816339 cites W2083764282 @default.
• W2129816339 cites W2092706522 @default.
• W2129816339 cites W2103509522 @default.
• W2129816339 cites W2118482494 @default.
• W2129816339 cites W2118672029 @default.
• W2129816339 cites W2125975478 @default.
• W2129816339 cites W2128544796 @default.
• W2129816339 cites W2139184637 @default.
• W2129816339 cites W2147713995 @default.
• W2129816339 cites W2148737987 @default.
• W2129816339 cites W2149214723 @default.
• W2129816339 cites W2155851270 @default.
• W2129816339 cites W2158303916 @default.
• W2129816339 cites W2158751879 @default.
• W2129816339 cites W2166392962 @default.
• W2129816339 cites W2171752072 @default.
• W2129816339 doi "https://doi.org/10.1186/s13550-015-0142-y" @default.
• W2129816339 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4639542" @default.
• W2129816339 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26553049" @default.
• W2129816339 hasPublicationYear "2015" @default.
• W2129816339 type Work @default.
• W2129816339 sameAs 2129816339 @default.
• W2129816339 citedByCount "18" @default.
• W2129816339 countsByYear W21298163392016 @default.
• W2129816339 countsByYear W21298163392018 @default.
• W2129816339 countsByYear W21298163392019 @default.
• W2129816339 countsByYear W21298163392020 @default.
• W2129816339 countsByYear W21298163392021 @default.
• W2129816339 countsByYear W21298163392022 @default.
• W2129816339 countsByYear W21298163392023 @default.
• W2129816339 crossrefType "journal-article" @default.
• W2129816339 hasAuthorship W2129816339A5002069722 @default.
• W2129816339 hasAuthorship W2129816339A5011666650 @default.
• W2129816339 hasAuthorship W2129816339A5023339336 @default.
• W2129816339 hasAuthorship W2129816339A5026596873 @default.
• W2129816339 hasAuthorship W2129816339A5030459772 @default.
• W2129816339 hasAuthorship W2129816339A5034821195 @default.
• W2129816339 hasAuthorship W2129816339A5040369608 @default.
• W2129816339 hasAuthorship W2129816339A5056704467 @default.
• W2129816339 hasAuthorship W2129816339A5079645152 @default.
• W2129816339 hasBestOaLocation W21298163391 @default.
• W2129816339 hasConcept C126322002 @default.
• W2129816339 hasConcept C143998085 @default.
• W2129816339 hasConcept C146957229 @default.
• W2129816339 hasConcept C2776297358 @default.
• W2129816339 hasConcept C2776694085 @default.
• W2129816339 hasConcept C2777389519 @default.
• W2129816339 hasConcept C2779066768 @default.
• W2129816339 hasConcept C2781025020 @default.
• W2129816339 hasConcept C2989005 @default.
• W2129816339 hasConcept C2993559085 @default.
• W2129816339 hasConcept C71924100 @default.
• W2129816339 hasConcept C80115893 @default.
• W2129816339 hasConceptScore W2129816339C126322002 @default.
• W2129816339 hasConceptScore W2129816339C143998085 @default.
• W2129816339 hasConceptScore W2129816339C146957229 @default.
• W2129816339 hasConceptScore W2129816339C2776297358 @default.
• W2129816339 hasConceptScore W2129816339C2776694085 @default.
• W2129816339 hasConceptScore W2129816339C2777389519 @default.
• W2129816339 hasConceptScore W2129816339C2779066768 @default.
• W2129816339 hasConceptScore W2129816339C2781025020 @default.
• W2129816339 hasConceptScore W2129816339C2989005 @default.
• W2129816339 hasConceptScore W2129816339C2993559085 @default.
• W2129816339 hasConceptScore W2129816339C71924100 @default.
• W2129816339 hasConceptScore W2129816339C80115893 @default.
• W2129816339 hasFunder F4320321687 @default.

• next